StockNews.AI
GILD
StockNews.AI
33 days

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

1. Global HIV market projected to reach $32.1 billion by 2033. 2. Gilead's Biktarvy remains a leading treatment option in HIV. 3. Pipeline products unlikely to surpass Biktarvy's commercial success. 4. Significant unmet needs in HIV treatment still persist. 5. Gilead expected to remain a key player in HIV space.

9m saved
Insight
Article

FAQ

Why Bullish?

Gilead's position as a leading player coupled with market growth expectations indicates potential for price appreciation. Historical precedents show that market leadership in a growing sector can lead to stock price increases.

How important is it?

The article discusses key market metrics and Gilead's strategic positioning in the HIV market, which directly impacts investor sentiment and stock price.

Why Long Term?

The significant forecast period (2023-2033) suggests long-term growth potential. The HIV market's expansion may result in sustained revenue growth for Gilead over the next decade.

Related Companies

GSKJanssenMRKVTRSABBV
Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.The report provides an in-depth assessment of the HIVs market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.Over four decades ago, researchers identified the human immunodeficiency virus (HIV) as the causative agent of a then-mysterious new illness, acquired immunodeficiency syndrome (AIDS). A member of the Lentivirus genus, HIV belongs to the family of retroviruses, RNA viruses with the ability to reverse transcribe their single-stranded RNA genome into double-stranded DNA and integrate it into the host's genome (Barre-Sinoussi et al., 1983; Gallo et al., 1983; McCutchan et al., 1996). Since the start of the epidemic, around 88.4 million people have become infected, and 42.3 million have died from AIDS-related illnesses (UNAIDS, 2024). In the decades since the approval of the first antiretroviral therapy (ART)-GlaxoSmithKline's (GSK's) Retrovir (azidothymidine) in 1987-the HIV market has become highly competitive, with a wide range of options now available for both treatment and prophylaxis of HIV. This includes the availability of once-daily, single-tablet regimens (STRs) for HIV treatment such as Gilead's Biktarvy (bictegravir/emtricitabine/TAF) and Genvoya (elvitegravir/cobicistat/emtricitabine/TAF), as well as long-acting injectables including Gilead's Sunlenca (lenacapavir) for the treatment of multidrug-resistant HIV and GSK's Apretude (cabotegravir) for pre-exposure prophylaxis (PrEP).The analyst projects the global HIV marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)-to experience modest growth during the forecast period. The report covers only HIV-1 because the strain is responsible for the majority of diagnosed prevalent cases of HIV in the 7MM. Furthermore, HIV-2 infections are mainly reported in sub-Saharan African countries, which are not included in the scope of this report.The model covers the market forecast for marketed products and Phase III pipeline products. The base year of this model is 2023, and the forecast period is 2023-33.Key Highlights Report deliverables include a Pdf and an Excel-based forecast modelForecast includes the 7 major markets (7MM)Forecast covers the period 2023-2033 Scope Overview of HIV including etiology, pathophysiology and epidemiology.Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.HIV market outlook from 2023-2033, including annual cost of therapy per patient, and total sales revenues per product for each of the 7MM. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipelines.Develop business strategies by understanding the trends shaping and driving the 7MM HIV market.Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HIV market in the future.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered:1 HIV: Executive Summary1.1 HIV market to reach $32.1 billion by 20331.2 Gilead Sciences to remain leading player in the HIV space1.3 Despite major advances in ART, significant unmet needs remain1.4 Pipeline STRs will not surpass Biktarvy in terms of commercial success1.5 What do physicians think?2 Introduction2.1 Catalyst2.2 Related reports2.3 Upcoming reports3 Disease Overview3.1 Etiology and pathophysiology3.1.1 Etiology3.1.2 Pathophysiology3.2 Clinical stages of HIV infection3.3 Prognosis and quality of life4 Epidemiology4.1 Disease background4.2 Risk factors and comorbidities4.3 Global and historical trends4.3.1 Total prevalence of HIV4.3.2 Diagnosed prevalence of HIV4.3.3 Diagnosed incidence of HIV4.4 7MM forecast methodology4.4.1 Sources4.4.2 Sources not used4.4.3 Forecast assumptions and methods4.4.4 Total prevalent cases of HIV4.4.5 Diagnosed prevalent cases of HIV4.4.6 Diagnosed prevalent cases of HIV with hepatitis B virus/hepatitis C virus coinfection4.4.7 Diagnosed prevalent cases of HIV on antiretroviral treatment4.4.8 Diagnosed incident cases of HIV4.4.9 Prophylactic population on pre-exposure prophylaxis4.4.10 Prophylactic population on post-exposure prophylaxis4.5 Epidemiological forecast for HIV (2023-33)4.5.1 Total prevalent cases of HIV4.5.2 Diagnosed prevalent cases of HIV4.5.3 Age-specific diagnosed prevalent cases of HIV4.5.4 Sex-specific diagnosed prevalent cases of HIV4.5.5 Diagnosed prevalent cases of HIV with coinfection4.5.6 Diagnosed prevalent cases of HIV on antiretroviral treatment4.5.7 Diagnosed incident cases of HIV4.5.8 Age-specific diagnosed incident cases of HIV4.5.9 Sex-specific diagnosed prevalent cases of HIV4.5.10 Prophylactic population on pre-exposure prophylaxis4.5.11 Prophylactic population on post-exposure prophylaxis4.6 Discussion4.6.1 Epidemiological forecast insight4.6.2 COVID-19 impact4.6.3 Limitations of the analysis4.6.4 Strengths of the analysis5 Disease Management5.1 Diagnosis and treatment overview5.2 KOL insights on disease management6 Current Treatment Options6.1 Overview7 Unmet Needs and Opportunity Assessment7.1 Overview7.2 Better prevention and testing, and earlier diagnosis7.3 Improvements to mental health, social and ancillary care services7.4 More affordable and accessible prophylactic and therapeutic options7.5 Addressing drug resistance8 R&D Strategies8.1 Overview8.1.1 Stem cell transplants leading to HIV remission8.1.2 Long-acting therapy options for prevention8.1.3 Germline-targeting strategies in HIV vaccine development8.1.4 Two-drug single-tablet regimens8.2 Clinical trials design8.2.1 Inclusion of underrepresented populations8.2.2 Adoption of innovative trial methodologies8.2.3 Emphasis on long-acting prevention and treatment modalities9 Pipeline Assessment9.1 Overview9.2 Promising drugs in clinical development10 Pipeline Valuation Analysis10.1 Overview10.2 Competitive Assessment11 Current and Future Players11.1 Overview11.2 Deal-making trends12 Market Outlook12.1 Global markets (7MM)12.1.1 Forecast12.1.2 Drivers and barriers - global issues12.2 US12.2.1 Forecast12.2.2 Key events12.2.3 Drivers and barriers12.3 5EU12.3.1 Forecast12.3.2 Key events12.3.3 Drivers and barriers12.4 Japan12.4.1 Forecast12.4.2 Key events12.4.3 Drivers and barriersCompanies Featured GileadJanssenMerckViiV HealthcareGSKAbbVieTheratechnologiesRocheCytodyn For more information about this report visit https://www.researchandmarkets.com/r/ssfdvx About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News